Serum and Urine Level of IP-10 in Patients with HCV infection Based on Clinical and Virological Markers
|
Zahra Moallemi , Jamshid Ayatollahi * , Masoud Doosti |
Associate Professor, Infectious and Tropical Diseases Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran |
|
Abstract: (3772 Views) |
Abstract
Background and Aims: IP-10 molecule is a new biomarker to predict response to treatment in chronic HCV infection. Also urine IP-10 has been suggested as a biomarker in other infections. But already, it has low data in urine as well as serum level of IP-10 for HCV infection. The aim of this study was to assess urine and serum level of IP-10 in patients with type 1 and 3a HCV infection.
Materials and Methods: In this case-control study, 105 patients with HCV infection were involved in three 35 people groups. Blood and urine sample of all patients was collected to determine IP-10 level. Finally, data analysis was reported using SPSS, mean statistics analysis and T test.
Results: The age mean was 41.6±11.2 ranging 21-68. Urine and serum level of IP-10 in patient group was significantly higher than control (p=0.001). Serum level of IP-10 based on HCV genotype was higher significantly in genotype 1a than 3a (p=0.001) but there was no significant difference of urine IP-10 level between genotypes 1a and 3a.
Conclusions: The results show IP-10 is a proper marker to determine the prognosis of fibrosis and progress liver inflammation and on the other hand, the prediction of response to treatment differs in various genotypes of HCV infection.
|
|
Keywords: Hepatitis C, IP-10, serum and urine, genotype 3a and 1a |
|
Full-Text [PDF 534 kb]
(1314 Downloads)
|
Type of Study: Original article |
Subject:
General Received: 2016/08/30 | Accepted: 2016/09/9 | Published: 2016/09/9
|
|
|
- IP-10 is a proper marker to determine the prognosis of fibrosis and progress liver inflammation.
- The prediction of response to treatment differs in various genotypes of HCV infection.
|